… reported to be without bearing on the safety or efficacy of lixisenatide treatment. In conclusion,
lixisenatide significantly improved all primary and secondary outcome measures in doses …

… by Lixisenatide occurred in a strictly glucose-dependent manner. In animal models of diabetes,
Lixisenatide … Lixisenatide also delayed gastric emptying and reduced food intake. The …

… 3034 patients to lixisenatide and 3034 to placebo. All but 5 patients (3 patients in the lixisenatide
group and 2 in the placebo group) received at least one dose of lixisenatide or placebo. …

… Phase II trials have shown that lixisenatide 20 µg once daily … The efficacy and safety of
lixisenatide once daily is being … This, along with the pronounced effect of lixisenatide on …

… trial, we assessed the effect of lixisenatide on the progression of motor disability in persons
… in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-…

… This article summarizes the milestones in the development of lixisenatide, leading to this …
programme for lixisenatide was initiated in May 2008 and examined the use of lixisenatide both …

… Additionally, lixisenatide delays gastric emptying and increases satiety. Lixisenatide has been
… In the GetGoal clinical trial series, lixisenatide resulted in a hemoglobin A 1C reduction of …

… distribution of lixisenatide after subcutaneous administration is 100 L. Lixisenatide is thought
… Significant changes in renal function may influence the elimination of lixisenatide. Patients …

Introduction: Lixisenatide is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor
agonist (GLP-1RA) used in the treatment of type 2 diabetes mellitus (T2DM). It is used in …

… Improved tolerability with lixisenatide was reflected by the fact that more lixisenatide-treated
subjects tolerated the target dose of 20 µg/day. The safety profile of lixisenatide in this study …